Literature DB >> 20644167

Genetic sphingosine kinase 1 deficiency significantly decreases synovial inflammation and joint erosions in murine TNF-alpha-induced arthritis.

DeAnna A Baker1, Jeremy Barth, Raymond Chang, Lina M Obeid, Gary S Gilkeson.   

Abstract

Sphingosine kinase 1 (SphK1) is an enzyme that converts sphingosine to bioactive sphingosine-1-phosphate. Recent in vitro data suggest a potential role of SphK1 in TNF-alpha-mediated inflammation. Our aims in this study were to determine the in vivo significance of SphK1 in TNF-alpha-mediated chronic inflammation and to define which pathogenic mechanisms induced by TNF-alpha are SphK1 dependent. To pursue these aims, we studied the effect of SphK1 deficiency in an in vivo model of TNF-alpha-induced chronic inflammatory arthritis. Transgenic hTNF-alpha mice, which develop spontaneous inflammatory erosive arthritis beginning at 14-16 wk, were crossed with SphK1 null mice (SphK1(-/-)), on the C57BL6 genetic background. Beginning at 4 mo of age, hTNF/SphK1(-/-) mice had significantly less severe clinically evident paw swelling and deformity, less synovial and periarticular inflammation, and markedly decreased bone erosions as measured quantitatively through micro-CT images. Mechanistically, the mice lacking SphK1 had less articular cyclooxygenase 2 protein and fewer synovial Th17 cells than did hTNF/SphK1(+/+) littermates. Microarray analysis and real-time RT-PCR of the ankle synovial tissue demonstrated that hTNF/SphK1(-/-) mice had increased transcript levels of suppressor of cytokine signaling 3 compared with hTNF/SphK1(+/+) mice, likely also contributing to the decreased inflammation in the SphK1-deficient mice. Finally, significantly fewer mature osteoclasts were detected in the ankle joints of hTNF/SphK1(-/-) mice compared with hTNF/SphK1(+/+) mice. These data indicate that SphK1 plays a key role in hTNF-alpha-induced inflammatory arthritis via impacting synovial inflammation and osteoclast number.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20644167      PMCID: PMC2942019          DOI: 10.4049/jimmunol.1000644

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  42 in total

1.  Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factor-alpha signaling.

Authors:  Pu Xia; Lijun Wang; Paul A B Moretti; Nathaniel Albanese; Fugui Chai; Stuart M Pitson; Richard J D'Andrea; Jennifer R Gamble; Mathew A Vadas
Journal:  J Biol Chem       Date:  2002-01-02       Impact factor: 5.157

2.  Molecular cloning and functional characterization of murine sphingosine kinase.

Authors:  T Kohama; A Olivera; L Edsall; M M Nagiec; R Dickson; S Spiegel
Journal:  J Biol Chem       Date:  1998-09-11       Impact factor: 5.157

Review 3.  Sphingolipids in inflammation: roles and implications.

Authors:  B J Pettus; C E Chalfant; Y A Hannun
Journal:  Curr Mol Med       Date:  2004-06       Impact factor: 2.222

4.  Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1.

Authors:  Mehrdad Matloubian; Charles G Lo; Guy Cinamon; Matthew J Lesneski; Ying Xu; Volker Brinkmann; Maria L Allende; Richard L Proia; Jason G Cyster
Journal:  Nature       Date:  2004-01-22       Impact factor: 49.962

5.  The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha.

Authors:  Benjamin J Pettus; Jacek Bielawski; Anna M Porcelli; Davis L Reames; Korey R Johnson; Jason Morrow; Charles E Chalfant; Lina M Obeid; Yusuf A Hannun
Journal:  FASEB J       Date:  2003-08       Impact factor: 5.191

6.  Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum.

Authors:  T Saxne; M A Palladino; D Heinegård; N Talal; F A Wollheim
Journal:  Arthritis Rheum       Date:  1988-08

7.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.

Authors:  M J Elliott; R N Maini; M Feldmann; J R Kalden; C Antoni; J S Smolen; B Leeb; F C Breedveld; J D Macfarlane; H Bijl
Journal:  Lancet       Date:  1994-10-22       Impact factor: 79.321

8.  Role of ceramide in stimulation of the transcription of cytosolic phospholipase A2 and cyclooxygenase 2.

Authors:  M Hayakawa; S Jayadev; M Tsujimoto; Y A Hannun; F Ito
Journal:  Biochem Biophys Res Commun       Date:  1996-03-27       Impact factor: 3.575

9.  Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.

Authors:  J Keffer; L Probert; H Cazlaris; S Georgopoulos; E Kaslaris; D Kioussis; G Kollias
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

10.  Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation.

Authors:  Craig A Murphy; Claire L Langrish; Yi Chen; Wendy Blumenschein; Terrill McClanahan; Robert A Kastelein; Jonathon D Sedgwick; Daniel J Cua
Journal:  J Exp Med       Date:  2003-12-08       Impact factor: 14.307

View more
  46 in total

Review 1.  Sphingosine-1-phosphate and immune regulation: trafficking and beyond.

Authors:  Hongbo Chi
Journal:  Trends Pharmacol Sci       Date:  2010-12-14       Impact factor: 14.819

Review 2.  Sphingosine-1-phosphate signaling and its role in disease.

Authors:  Michael Maceyka; Kuzhuvelil B Harikumar; Sheldon Milstien; Sarah Spiegel
Journal:  Trends Cell Biol       Date:  2011-10-14       Impact factor: 20.808

Review 3.  Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond.

Authors:  Gregory T Kunkel; Michael Maceyka; Sheldon Milstien; Sarah Spiegel
Journal:  Nat Rev Drug Discov       Date:  2013-08-19       Impact factor: 84.694

4.  Periodontal inflammation and alveolar bone loss induced by Aggregatibacter actinomycetemcomitans is attenuated in sphingosine kinase 1-deficient mice.

Authors:  H Yu; C Sun; K M Argraves
Journal:  J Periodontal Res       Date:  2015-04-20       Impact factor: 4.419

Review 5.  Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors.

Authors:  K Alexa Orr Gandy; Lina M Obeid
Journal:  Biochim Biophys Acta       Date:  2012-07-16

Review 6.  Sphingosine 1-phosphate in coagulation and inflammation.

Authors:  Hideru Obinata; Timothy Hla
Journal:  Semin Immunopathol       Date:  2011-07-31       Impact factor: 9.623

7.  Sphingosine kinase and sphingosine-1-phosphate: regulators in autoimmune and inflammatory disease.

Authors:  Ashley J Snider
Journal:  Int J Clin Rheumtol       Date:  2013-08-01

8.  Sphingosine-1-phosphate lyase deficiency produces a pro-inflammatory response while impairing neutrophil trafficking.

Authors:  Maria L Allende; Meryem Bektas; Bridgin G Lee; Eliana Bonifacino; Jiman Kang; Galina Tuymetova; WeiPing Chen; Julie D Saba; Richard L Proia
Journal:  J Biol Chem       Date:  2010-12-20       Impact factor: 5.157

9.  SPHK-2 Promotes the Particle-Induced Inflammation of RAW264.7 by Maintaining Consistent Expression of TNF-α and IL-6.

Authors:  Guangpu Yang; Minghui Gu; Weishen Chen; Wenhua Liu; Yinbo Xiao; Haixing Wang; Weiming Lai; Guoyan Xian; Ziji Zhang; Ziqing Li; Puyi Sheng
Journal:  Inflammation       Date:  2018-08       Impact factor: 4.092

10.  Spinster 2, a sphingosine-1-phosphate transporter, plays a critical role in inflammatory and autoimmune diseases.

Authors:  Michael S Donoviel; Nitai C Hait; Subramaniam Ramachandran; Michael Maceyka; Kazuaki Takabe; Sheldon Milstien; Tamas Oravecz; Sarah Spiegel
Journal:  FASEB J       Date:  2015-08-31       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.